Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 28;11(3):e70151.
doi: 10.1002/trc2.70151. eCollection 2025 Jul-Sep.

Long-term value of lecanemab to individuals and families

Bryan Tysinger  1 , Yifan Wei  2 , Hanke Heun-Johnson  1 , Julie M Zissimopoulos  1
Affiliations

Long-term value of lecanemab to individuals and families

Bryan Tysinger et al. Alzheimers Dement (N Y). .

Abstract

Introduction: An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment initiation.

Methods: We used data from a nationally representative sample of middle aged and older Americans combined with data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) on AD progression and data on lecanemab treatment effects from Clarity AD clinical trials. We use dynamic microsimulation modeling to quantify the long-term health and economic value of lecanemab for persons living with AD and their care partners.

Results: We quantified five measures of value: quality of life of the persons living with AD and their care partners, medical costs, caregiving costs, and earnings, and estimated that lecanemab had a value of $21,398 relative to no treatment after 4 years and $37,943 after 10 years. Extending the treatment to 48 months resulted in a value of $42,821 relative to no treatment after 4 years and $95,311 after 10 years. Forty-eight months of a similar next-generation therapy but with 50% efficacy in slowing cognitive and functional decline resulted in a value of $82,116 relative to no treatment after 4 years and $189,691 after 10 years.

Discussion: Over time, lecanemab treatment reduced medical costs, hours of care required from care partners, and improved quality of life. There is much value to be gained with next-generation treatments that have a larger impact on slowing decline. Considering a wider range of outcomes in future assessments will provide a more complete understanding of value to support decision making about treatment initiation and about reimbursement for payers.

Highlights: There is significant value of lecanemab for persons with mild cognitive impairment or mild dementia.Over time, lecanemab reduces medical costs, caregiver hours, and improves the quality of life of persons living with Alzheimer's disease (AD) and their care partners.A next-generation treatment for AD with similar features to lecanemab but higher efficacy, more than doubles the value.Assessing therapy value supports decision making by patients and their health-care providers.

Keywords: disease‐modifying therapy; economic value; quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. Author disclosures are available in the supporting information.

References

    1. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement. 2024;10(2):e12465. doi: 10.1002/trc2.12465 - DOI - PMC - PubMed
    1. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19(4):1598‐1695. doi: 10.1002/alz.13016 - DOI - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9‐21. doi: 10.1056/NEJMoa2212948 - DOI - PubMed
    1. Cohen S, van Dyck CH, Gee M, et al. Lecanemab Clarity AD: quality‐of‐life results from a randomized, double‐blind phase 3 trial in early Alzheimer's disease. J Prev Alzheimers Dis. 2023;10(4):771‐777. doi: 10.14283/jpad.2023.123 - DOI - PubMed
    1. Wright AC, Lin GA, Whittington MD, et al. The effectiveness and value of lecanemab for early Alzheimer disease: a summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum. J Manag Care Spec Pharm. 2023;29(9):1078‐1083. doi: 10.18553/jmcp.2023.29.9.1078 - DOI - PMC - PubMed

LinkOut - more resources